Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Inclusion Criteria:

- Patient is currently receiving treatment with ceritinib within a Novartis-sponsored
study which has fulfilled the requirements for the primary objective and, in the
opinion of the Investigator, would benefit from continued treatment.

- Patient has demonstrated compliance, as assessed by the investigator, with the parent
study protocol requirements.

- Willingness and ability to comply with scheduled visits, treatment plans and any other
study procedures.

- Written informed consent obtained prior to enrolling in the roll-over study and
receiving study medication. If consent cannot be expressed in writing, it must be
formally documented and witnessed via an independent trusted witness.

Exclusion Criteria:

- Patient has been permanently and prematurely discontinued from ceritinib study
treatment in the parent study due to any reason.

- Patient currently has unresolved toxicities for which ceritinib dosing has been
interrupted in the parent study.

- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
female after conception and until the termination of gestation, confirmed by a
positive serum hCG laboratory test.

- Women of child-bearing potential, defined as all women physiologically capable of
becoming pregnant, unless they are using highly effective methods of contraception
during dosing and for 3 months afer stopping ceritinib treatment.

- Sexually active males unless they use a condom during intercourse while taking drug
and for 3 months after stopping ceritinib and should not father a child for at least 3
months after the last dose of treatment.